Argenx posts $1.5B Q2 sales as Vyvgart label expands to all gMG

Argenx reported Q2 product net sales of $1.52 billion, up 60% from a year earlier, driven by an expanded Vyvgart label.

"Our strong second quarter performance reflects continued execution of our Vision 2030 strategy," Chief Executive Officer Karen Massey said.

Operating profit rose to $494 million from $201 million a year earlier, while net income reached $472 million, or $7.58 per share, compared with $245 million, or $4.02 per share, in the same period of 2025. The company ended the quarter with $5.2 billion in cash and current financial assets, up from $4.4 billion at year-end 2025.

The results show argenx's growing commercial momentum as it pushes toward its Vision 2030 goal of treating 50,000 patients globally. The company expects registrational readouts for Vyvgart in autoimmune myositis in the third quarter and for empasiprubart in multifocal motor neuropathy in the fourth quarter, offering potential for further label expansion.

The company launched Vyvgart and Vyvgart Hytrulo for anti-AChR antibody negative generalized myasthenia gravis during the quarter, expanding the addressable patient population to all gMG serotypes. Vyvgart is now the first-and-only approved treatment for all serotypes of adult gMG patients.

Total operating expenses rose to $1.05 billion from $766 million, reflecting higher research and development costs of $486 million and selling, general and administrative expenses of $417 million. R&D spending increased as argenx advanced its pipeline, which by year-end 2026 is expected to include 10 molecules in clinical development.

The pipeline includes empasiprubart (anti-C2), being evaluated in registrational studies for multifocal motor neuropathy and CIDP, and adimanebart (MuSK agonist), along with earlier-stage candidates ARGX-121 (anti-IgA) and ARGX-109 (anti-IL-6).

The strong quarter and expanded label position argenx to capture a larger share of the gMG market, where it competes with UCB's Rystiggo and Johnson & Johnson's nipocalimab. Investors will watch the myositis readout in the third quarter as the next major event for Vyvgart's expansion into rheumatology.

This article is for informational purposes only and does not constitute investment advice.